Filtros de búsqueda

Lista de obras de Edith Álvarez Pérez

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

artículo científico publicado en 2015

3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer

artículo científico publicado en 2009

5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

artículo científico publicado en 2015

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast ⬇️

artículo científico publicado el 2 de mayo de 2013

A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2013

A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis

artículo científico publicado en 2007

A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations

artículo científico publicado en 2007

A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines

artículo científico publicado en 2011

A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103) ⬇️

artículo científico publicado el 1 de mayo de 2012

A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.

artículo científico publicado en 2005

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial

artículo científico publicado en 2010

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

artículo científico publicado en 2003

A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen

artículo científico publicado en 2006

ACCO: ASCO Core Curriculum Outline

scientific article published on 22 February 2005

Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104

artículo científico publicado en 2010

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

artículo científico publicado en 2015

Adjuvant chemotherapy in older women with early-stage breast cancer

artículo científico publicado en 2009

Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer

artículo científico publicado en 2006

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

artículo científico publicado en 2014

Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials

artículo científico publicado en 2002

Adjuvant therapy of triple negative breast cancer

artículo científico publicado en 2010

Adjuvant therapy trials of radiotherapy and systemic treatment for breast cancer ⬇️

artículo científico publicado el 1 de enero de 2002

Adjuvant trastuzumab for HER2-positive early breast cancer

artículo científico publicado en 2010

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

artículo científico publicado en 2006

Advances in adjuvant therapy for breast cancer

artículo científico publicado en 2006

Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries

artículo científico publicado en 2015

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

artículo científico publicado en 2006

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

artículo científico publicado en 2007

An integrated model of the transcriptome of HER2-positive breast cancer

artículo científico publicado en 2013

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience

artículo científico publicado en 2013

Anthracycline vs nonanthracycline adjuvant therapy for breast cancer

artículo científico publicado en 2004

Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends

artículo científico publicado en 2009

Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status ⬇️

artículo científico publicado el 17 de junio de 2013

Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors

artículo científico publicado en 2016

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

artículo científico publicado en 2015

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

artículo científico publicado en 2008

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831

artículo científico publicado en 2014

Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer

artículo científico publicado en 2009

Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways

artículo científico publicado en 2008

Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers

artículo científico publicado en 2014

Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy

artículo científico publicado en 2017

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

artículo científico publicado en 2009

Breast cancer brain metastases: Molecular subtype, treatment and survival

artículo científico publicado en 2016

Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups

artículo científico publicado en 2010

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

artículo científico publicado en 2011

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

artículo científico publicado en 2008

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

artículo científico publicado en 2014

Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology an

artículo científico publicado en 2016

Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol

artículo científico publicado en 2018

Changes to adjuvant systemic therapy in breast cancer: a decade in review

artículo científico publicado en 2010

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

artículo científico publicado en 2012

Clinical cardiac tolerability of trastuzumab

artículo científico publicado en 2004

Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?

artículo científico publicado en 2011

Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay

artículo científico publicado en 2010

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

artículo científico publicado en 2014

Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population

artículo científico publicado en 2009

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

scientific article published on 01 June 2002

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

artículo científico publicado en 2008

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

scientific article published on 24 June 2019

Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.

artículo científico publicado en 2015

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

scientific article published on 11 March 2019

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

artículo científico publicado en 2007

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

artículo científico publicado en 2018

Current and emerging targeted therapies for metastatic breast cancer ⬇️

artículo científico publicado el 17 de octubre de 2011

Current treatment options for metastatic breast cancer: what now?

artículo científico publicado el 1 de noviembre de 2011

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

artículo científico publicado en 2009

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance

scientific article published on September 2008

Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.

artículo científico publicado en 2011

Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations ⬇️

artículo científico publicado el 10 de febrero de 2012

Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer.

artículo científico publicado en 2012

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis

artículo científico publicado en 2019

Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity

artículo científico publicado en 2015

Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)

artículo científico publicado en 2007

Dual HER2 blockade: preclinical and clinical data

artículo científico publicado en 2014

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

article

Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.

artículo científico publicado en 2013

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

scientific article published on 01 September 2004

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

scientific article published on 05 July 2006

Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.

artículo científico publicado en 2015

Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

scientific article published on 26 February 2019

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

artículo científico publicado en 2007

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

artículo científico publicado en 2015

Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17

article

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

scientific article published on 13 March 2010

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

artículo científico publicado en 2017

Erratum: Dual HER2 blockade: preclinical and clinical data.

artículo científico publicado en 2014

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory

artículo científico publicado en 2008

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

artículo científico publicado en 2006

Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole

artículo científico publicado en 2014

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

artículo científico publicado en 2015

Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study

artículo científico publicado en 2009

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

artículo científico publicado en 2010

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial

artículo científico publicado en 2013

Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007.

artículo científico publicado en 2008

Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform

artículo científico publicado en 2010

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole

artículo científico publicado en 2011

Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients

artículo científico publicado en 2020

Folate receptor-α (FOLR1) expression and function in triple negative tumors

artículo científico publicado en 2015

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

artículo científico publicado en 2011

Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.

artículo científico publicado en 2006

Future options with trastuzumab for primary systemic and adjuvant therapy

artículo científico publicado en 2004

Gene expression, single nucleotide variant and fusion transcript discovery in archival material from breast tumors

artículo científico publicado en 2013

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

artículo científico publicado en 2018

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial

artículo científico publicado en 2017

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

artículo científico publicado en 2015

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

artículo científico publicado en 2010

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

artículo científico publicado en 2015

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

artículo científico publicado en 2006

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

artículo científico publicado en 2006

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization

scientific article published on 01 February 2002

HER2 testing: current status and future directions.

artículo científico

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial ⬇️

artículo científico publicado en 2015

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial ⬇️

artículo científico publicado en 2017

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).

artículo científico publicado en 2018

How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer? ⬇️

artículo científico publicado el 14 de enero de 2013

IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.

artículo científico publicado en 2017

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.

scientific article published on 12 February 2009

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

artículo científico publicado en 2013

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer

artículo científico publicado en 2009

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

artículo científico publicado en 2013

Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study

scientific article published on 15 September 2020

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

artículo científico publicado en 2013

Impact of library preparation on downstream analysis and interpretation of RNA-Seq data: comparison between Illumina PolyA and NuGEN Ovation protocol

artículo científico publicado en 2013

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain

artículo científico publicado en 2016

In newly diagnosed breast cancer, screening MRI of the contralateral breast detects mammographically occult cancer, even in elderly women: the mayo clinic in Florida experience

artículo científico publicado en 2010

Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31

scientific article published on 17 October 2019

Individualizing treatment to optimize survival outcomes in breast cancer

artículo científico publicado en 2013

Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing

artículo científico publicado en 2011

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

artículo científico publicado en 2008

International study on inter-reader variability for circulating tumor cells in breast cancer

artículo científico publicado en 2014

Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases

artículo científico publicado en 2020

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial

artículo científico publicado en 2016

Issues and controversies in the treatment of HER2 positive metastatic breast cancer

artículo científico publicado en 2007

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

artículo científico publicado en 2010

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

artículo científico publicado en 2012

Lack of publication bias related to results from trastuzumab study

artículo científico publicado en 2008

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

artículo científico publicado en 2014

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

artículo científico publicado en 2016

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

artículo científico publicado en 2008

Letrozole: present and future role in the treatment of breast cancer

artículo científico publicado en 2007

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

scientific article published on 21 September 2015

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

artículo científico publicado en 2015

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

artículo científico publicado en 2010

Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study

artículo científico publicado en 2009

Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial

artículo científico publicado en 2011

Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look?

artículo científico publicado en 2010

MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer ⬇️

artículo científico publicado el 2 de marzo de 2011

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy

artículo científico publicado en 2015

N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer

artículo científico publicado en 2020

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

artículo científico publicado en 2006

Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer

artículo científico publicado en 2005

Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer

artículo científico publicado en 2012

New developments in metastatic breast cancer: general discussion

artículo científico publicado en 2013

New developments in metastatic breast cancer: integrating recent data into clinical practice

artículo científico publicado en 2013

New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois

artículo científico publicado el 1 de agosto de 2011

New therapies in the treatment of breast cancer

artículo científico publicado en 2006

New treatment paradigms for optimizing survival in advanced and metastatic breast cancer

artículo científico publicado en 2012

North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer

artículo científico publicado en 2005

North Central Cancer Treatment Group--achievements and perspectives

artículo científico publicado en 2008

North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane

artículo científico publicado en 2012

Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable

scientific article published on February 2008

Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer ⬇️

artículo científico publicado el 27 de agosto de 2012

Optimizing adjuvant chemotherapy in early-stage breast cancer.

artículo científico publicado en 2005

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

artículo científico publicado en 2012

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).

artículo científico publicado en 2016

Patient Age and Preoperative Breast MRI in Women With Breast Cancer: Biopsy and Surgical Implications ⬇️

artículo científico publicado el 5 de enero de 2011

Perspectives from the American Society of Clinical Oncology 2014 Conference: breast cancer highlights

artículo científico publicado en 2014

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

artículo científico publicado en 2005

Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.

artículo científico publicado en 2013

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer

artículo científico publicado en 2014

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients

artículo científico publicado en 2015

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial ⬇️

artículo científico publicado el 1 de abril de 2012

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer ⬇️

artículo científico publicado el 4 de febrero de 2013

Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial

artículo científico publicado en 2005

Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer

artículo científico publicado en 2004

Phase II trial of dolastatin-10 in patients with advanced breast cancer

artículo científico publicado en 2005

Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.

artículo científico publicado en 2010

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

artículo científico publicado en 2008

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0

artículo científico publicado el 10 de enero de 2011

Phase III evaluation of fluoxetine for treatment of hot flashes

artículo científico publicado en 2002

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane ⬇️

artículo científico publicado en 2015

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

artículo científico publicado en 2007

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer

artículo científico publicado en 2008

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

artículo científico publicado en 2016

Pilot evaluation of gabapentin for treating hot flashes

artículo científico publicado en 2002

Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer ⬇️

artículo científico publicado el 11 de mayo de 2012

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

artículo científico publicado en 2011

Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial

artículo científico publicado en 2003

Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status ⬇️

artículo científico publicado el 7 de octubre de 2010

Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial

artículo científico publicado en 2015

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

artículo científico publicado en 2010

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial

artículo científico publicado en 2013

Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer

artículo científico publicado en 2015

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

artículo científico publicado en 2008

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study

artículo científico publicado en 2012

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

artículo científico publicado en 2014

Progress against solid tumors in danger: the metastatic breast cancer example

artículo científico publicado en 2012

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation

artículo científico publicado en 2015

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

artículo científico publicado en 2017

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

artículo científico publicado en 2015

Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples ⬇️

artículo científico publicado el 30 de enero de 2013

Quality of life after breast cancer surgery: What have we learned and where should we go next?

artículo científico publicado en 2009

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

artículo científico publicado en 2013

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

artículo científico publicado en 2011

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

artículo científico publicado el 11 de octubre de 2011

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial

artículo científico publicado en 2012

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

artículo científico publicado en 2009

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC

artículo científico publicado en 2015

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

article

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

artículo científico publicado en 2019

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

artículo científico publicado en 2004

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

artículo científico publicado en 2005

Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.

artículo científico publicado en 2006

Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium

artículo científico publicado el 1 de mayo de 2011

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

artículo científico publicado en 2013

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

article

Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization

artículo científico publicado en 2009

Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy

artículo científico publicado en 2009

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

artículo científico publicado en 2014

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

artículo científico publicado en 2014

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer ⬇️

artículo científico publicado el 20 de septiembre de 2011

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

artículo científico publicado en 2009

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

artículo científico publicado en 2019

Reply to C. Shah et al.

artículo científico publicado en 2016

Reply to E.A. Rakha et al.

artículo científico publicado en 2015

Reply to P.G. Gavin et al.

artículo científico publicado en 2015

Reply to S. Mahesh

artículo científico

Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors

scientific article published on 01 June 2006

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial ⬇️

artículo científico publicado en 2016

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).

artículo científico publicado en 2010

Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer ⬇️

artículo científico publicado el 31 de octubre de 2011

Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole

artículo científico publicado en 2005

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.

artículo científico publicado en 2005

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

artículo científico publicado en 2012

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831

artículo científico publicado en 2013

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study

artículo científico publicado en 2015

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline

artículo científico

TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression

artículo científico publicado en 2013

The Globalization of Cooperative Groups

artículo científico publicado en 2015

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

scientific article published on 18 January 2017

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

artículo científico publicado en 2006

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.

artículo científico publicado en 2015

The role of mammography in male patients with breast symptoms

scientific article published on 01 March 2007

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome

artículo científico publicado en 2013

Trastuzumab

artículo científico publicado en 2009

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study

artículo científico publicado en 2015

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

artículo científico publicado en 2016

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE

scientific article published on 18 July 2019

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

artículo científico publicado en 2014

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

artículo científico publicado en 2005

Treatment of HER2-positive breast cancer: current status and future perspectives.

artículo científico publicado en 2011

Treatment of metastatic breast cancer: looking towards the future

artículo científico publicado en 2008

Treatment options for breast cancer resistant to anthracycline and taxane

artículo científico publicado en 2009

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

artículo científico publicado en 2005

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

artículo científico publicado en 2013

Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas

artículo científico publicado en 2004

Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer

artículo científico publicado en 2010

Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer

artículo científico publicado en 2005

Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study

artículo científico publicado en 2003

Weekly paclitaxel in the adjuvant treatment of breast cancer.

artículo científico publicado en 2008

Weekly paclitaxel in women age 65 and above with metastatic breast cancer

artículo científico publicado en 2002

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

artículo científico publicado en 2009

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy

artículo científico publicado en 2010

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up

artículo científico publicado en 2015

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

artículo científico publicado en 2006

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda